Literature DB >> 17114651

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

Simona Soverini, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, Stefania Paolini, Michela Rondoni, Pier Paolo Piccaluga, Francesca Palandri, Panagiota Giannoulia, Giulia Marzocchi, Simona Luatti, Nicoletta Testoni, Ilaria Iacobucci, Daniela Cilloni, Giuseppe Saglio, Michele Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17114651     DOI： 10.1200/JCO.2006.08.9128

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Authors:  A Megan Cornelison; Hagop Kantarjian; Jorge Cortes; Elias Jabbour
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-28

2.  Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.

Authors:  Simona Soverini; Antonella Vitale; Angela Poerio; Alessandra Gnani; Sabrina Colarossi; Ilaria Iacobucci; Giuseppe Cimino; Loredana Elia; Annalisa Lonetti; Marco Vignetti; Stefania Paolini; Giovanna Meloni; Valeria di Maio; Cristina Papayannidis; Marilina Amabile; Anna Guarini; Michele Baccarani; Giovanni Martinelli; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

3.  Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).

Authors:  Ajoy K Samanta; Sandip N Chakraborty; Yan Wang; Ellen Schlette; E Premkumar Reddy; Ralph B Arlinghaus
Journal:  Genes Cancer       Date:  2010-04

Review 4.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

5.  Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Authors:  Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis J Giles; Weiqiang Zhao; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

Review 6.  Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Partow Kebriaei
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

Review 7.  Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Authors:  Simona Soverini; Caterina De Benedittis; Manuela Mancini; Giovanni Martinelli
Journal:  Oncologist       Date:  2016-03-31

8.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.

Authors:  Chika Kawajiri; Hiroaki Tanaka; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Toshiyuki Takagi; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2014-02-15       Impact factor: 2.490

9.  Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Authors:  Elias Jabbour; Daniel Jones; Hagop M Kantarjian; Susan O'Brien; Constantine Tam; Charles Koller; Jan A Burger; Gautam Borthakur; William G Wierda; Jorge Cortes
Journal:  Blood       Date:  2009-06-30       Impact factor: 22.113

10.  Dasatinib in chronic myeloid leukemia: a review.

Authors:  Dolly G Aguilera; Apostolia M Tsimberidou
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.